Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2025-2288

Published: 2025

Journal Articles

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Salomon Manier, Lauren E. Cain, Quan Chen, Sunny He, Kaustav Chatterjee, Hira Mian

Blood (2025) 146 (Supplement 1): 6341.

https://doi.org/10.1182/blood-2025-6341

Published: 2025

Journal Articles

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Shiyin Jiao, Jiawen Chen, Rajesh Kamalakar, Kojo Osei-Bonsu, Chetasi Talati, Steve Stricker, Tamas Vizkelety, Kaustav Chatterjee, Peter Voorhees

Blood (2025) 146 (Supplement 1): 4565.

https://doi.org/10.1182/blood-2025-4565

Published: 2025

Journal Articles

Examination of Real-World Outcomes and Health Care Resource Utilization in the Prevention and Treatment of Tumor Lysis Syndrome

Wynter Balcerski, PharmD, RPh, Kaustav Chatterjee, MD, Yvonne J Barnes, DNP,RN, Ed Drea, PharmD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-142795

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Examination of Real-World Outcomes and Health Care Resource Utilization in the Prevention and Treatment of Tumor Lysis Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy

Examination of Real-World Outcomes and Health Care Resource Utilization in the Prevention and Treatment of Tumor Lysis Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only